Literature DB >> 15930270

Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation.

Michael Milyavsky1, Yuval Tabach, Igor Shats, Neta Erez, Yehudit Cohen, Xiaohu Tang, Marina Kalis, Ira Kogan, Yosef Buganim, Naomi Goldfinger, Doron Ginsberg, Curtis C Harris, Eytan Domany, Varda Rotter.   

Abstract

The difficulty to dissect a complex phenotype of established malignant cells to several critical transcriptional programs greatly impedes our understanding of the malignant transformation. The genetic elements required to transform some primary human cells to a tumorigenic state were described in several recent studies. We took the advantage of the global genomic profiling approach and tried to go one step further in the dissection of the transformation network. We sought to identify the genetic signatures and key target genes, which underlie the genetic alterations in p53, Ras, INK4A locus, and telomerase, introduced in a stepwise manner into primary human fibroblasts. Here, we show that these are the minimally required genetic alterations for sarcomagenesis in vivo. A genome-wide expression profiling identified distinct genetic signatures corresponding to the genetic alterations listed above. Most importantly, unique transformation hallmarks, such as differentiation block, aberrant mitotic progression, increased angiogenesis, and invasiveness, were identified and coupled with genetic signatures assigned for the genetic alterations in the p53, INK4A locus, and H-Ras, respectively. Furthermore, a transcriptional program that defines the cellular response to p53 inactivation was an excellent predictor of metastasis development and bad prognosis in breast cancer patients. Deciphering these transformation fingerprints, which are affected by the most common oncogenic mutations, provides considerable insight into regulatory circuits controlling malignant transformation and will hopefully open new avenues for rational therapeutic decisions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15930270     DOI: 10.1158/0008-5472.CAN-04-3880

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  The effect of a novel frizzled 8-related antiproliferative factor on in vitro carcinoma and melanoma cell proliferation and invasion.

Authors:  Kristopher R Koch; Chen-Ou Zhang; Piotr Kaczmarek; Joseph Barchi; Li Guo; Hanief M Shahjee; Susan Keay
Journal:  Invest New Drugs       Date:  2011-09-20       Impact factor: 3.850

2.  On a fundamental structure of gene networks in living cells.

Authors:  Nataly Kravchenko-Balasha; Alexander Levitzki; Andrew Goldstein; Varda Rotter; A Gross; F Remacle; R D Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-05       Impact factor: 11.205

3.  Cross-analysis of gene and miRNA genome-wide expression profiles in human fibroblasts at different stages of transformation.

Authors:  Paola Ostano; Silvia Bione; Cristina Belgiovine; Ilaria Chiodi; Chiara Ghimenti; A Ivana Scovassi; Giovanna Chiorino; Chiara Mondello
Journal:  OMICS       Date:  2012 Jan-Feb

4.  SPATA18, a spermatogenesis-associated gene, is a novel transcriptional target of p53 and p63.

Authors:  Chamutal Bornstein; Ran Brosh; Alina Molchadsky; Shalom Madar; Ira Kogan-Sakin; Ido Goldstein; Deepavali Chakravarti; Elsa R Flores; Naomi Goldfinger; Rachel Sarig; Varda Rotter
Journal:  Mol Cell Biol       Date:  2011-02-07       Impact factor: 4.272

5.  Regulatory module involving FGF13, miR-504, and p53 regulates ribosomal biogenesis and supports cancer cell survival.

Authors:  Débora R Bublik; Slađana Bursać; Michal Sheffer; Ines Oršolić; Tali Shalit; Ohad Tarcic; Eran Kotler; Odelia Mouhadeb; Yonit Hoffman; Gilad Fuchs; Yishai Levin; Siniša Volarević; Moshe Oren
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-19       Impact factor: 11.205

6.  Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis.

Authors:  Noa Rivlin; Ran Brosh; Moshe Oren; Varda Rotter
Journal:  Genes Cancer       Date:  2011-04

7.  Cellular heterogeneity mediates inherent sensitivity-specificity tradeoff in cancer targeting by synthetic circuits.

Authors:  Mathieu Morel; Roman Shtrahman; Varda Rotter; Lior Nissim; Roy H Bar-Ziv
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-06       Impact factor: 11.205

8.  A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype.

Authors:  Yosef Buganim; Ido Goldstein; Doron Lipson; Michael Milyavsky; Sylvie Polak-Charcon; Corine Mardoukh; Hilla Solomon; Eyal Kalo; Shalom Madar; Ran Brosh; Marina Perelman; Roy Navon; Naomi Goldfinger; Iris Barshack; Zohar Yakhini; Varda Rotter
Journal:  PLoS One       Date:  2010-03-11       Impact factor: 3.240

9.  Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours.

Authors:  Subbaya Subramanian; Venugopal Thayanithy; Robert B West; Cheng-Han Lee; Andrew H Beck; Shirley Zhu; Erinn Downs-Kelly; Kelli Montgomery; John R Goldblum; Pancras C W Hogendoorn; Christopher L Corless; Andre M Oliveira; Sarah M Dry; Torsten O Nielsen; Brian P Rubin; Jonathan A Fletcher; Christopher D M Fletcher; Matt van de Rijn
Journal:  J Pathol       Date:  2010-01       Impact factor: 7.996

10.  Multiplexed and programmable regulation of gene networks with an integrated RNA and CRISPR/Cas toolkit in human cells.

Authors:  Lior Nissim; Samuel D Perli; Alexandra Fridkin; Pablo Perez-Pinera; Timothy K Lu
Journal:  Mol Cell       Date:  2014-05-15       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.